Ms Ma Hu Hsing, Venture Partner, TVM Capital, Germany will be speaking on the above topic at Pharma Partnering & Investment World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Ms Ma has been an advisor to TVM Capital since late 2004 and joined TVM Capital as Venture Partner for life sciences in 2007. She entered the life sciences industry in 2000 when she was a Senior Vice President at Vertex Management, where she co-led the Global Biotechnology Investment Division. Since 2003, she has been advising life sciences businesses wishing to expand or raise funds in Asia. Prior to 2000, she accumulated over 16 years of international investment, corporate finance and general management experience with Singapore Technologies, Banque Nationale de Paris, General Electric (USA), Morgan Grenfell, Booz, Allen & Hamilton and Price Waterhouse. Ms Ma holds a MSc in Biotechnology from the Johns Hopkins University, USA, a MBA from Manchester Business School, UK and a Bachelor of Accountancy from the National University of Singapore.
She will be discussing more about the points below:
Going beyond borders to build value in Asian healthcare investments
1. Uncovering the potential for internationalization of assets, developments and investors.
2. Understanding how US and European life science companies engage with their Asian counterparts and vice versa in the current economic climate
3. Recognizing investment strategies that private equity firms use for Asian life science investments versus investment strategies in the US and Europe.